Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.
Every day, countless Americans are forced to choose between meeting basic needs such as food, housing, or transportation and paying for their medications.
Companion diagnostic (CDx) tests play a critical role in personalising care by identifying optimal targeted therapies for patients based on their cancer’s unique genetic profile.
